drugset / Trial / NCT01387906

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

NCT01387906

Phase 4 Completed 20 enrolled Kenneth Beer Allergan · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.

Timeline

Start
2011-03
Primary completion
2012-03
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified Topical

Indications